Lilly(US:LLY) GLP1减重宝典·2025-07-09 12:00Core Viewpoint - Jim Gaffigan has successfully lost weight using the drug Mounjaro, which is a brand name for tirzepatide, a medication initially approved for type 2 diabetes treatment that also aids in weight loss [4][6]. Group 1: Drug Information - Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates both GLP-1 and GIP hormones to help regulate blood sugar levels [4]. - The FDA approved tirzepatide in May 2022 for improving blood sugar control in type 2 diabetes patients, and in November 2023, it was approved for weight loss in adults with obesity or overweight [4]. - In the SURMOUNT-5 clinical trial, participants treated with tirzepatide lost an average of 50.3 pounds (approximately 22.8 kg), with an average weight reduction of 20.2% [4]. Group 2: Personal Experience - Gaffigan initially had low expectations about the drug's effectiveness due to previous negative experiences shared by others [6]. - He struggled with weight gain for most of his adult life and faced challenges such as a slowing metabolism and knee pain [6]. - After consulting with his doctor, he decided to try the medication, which led to significant weight loss and improved health [6][8]. Group 3: Lifestyle Changes - Gaffigan maintains his health by walking in New York City and tracking his steps with an Apple Watch, despite not exercising extensively [8]. - His weight loss has positively impacted his family life, as his wife appreciates his improved health [8].